Transmucosal Drug Delivery Systems Market is expected to reach US$ 129.46 billion by 2031

Nasopulmonary Segment is Anticipated to Hold Largest Share of Transmucosal Drug Delivery Systems Market

According to our new research study on "Transmucosal Drug Delivery Systems Market Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis – by System, End User and Geography," the market is expected to grow from US$ 80.21 billion in 2023 to US$ 129.46 billion by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031. The rising adoption of drug delivery systems for disease management propels the transmucosal drug delivery systems market growth. Additionally, the development of new drug molecules and biological formulations is contributing to market growth. However, the concerns associated with biocompatibility and limited drug candidates hamper the market growth.

Drivers and Restraints Impacting Transmucosal Drug Delivery Systems Market Size

With improvements in medical devices and certain transdermal delivery technologies, the noninvasive mode of drug delivery is now gaining a competitive edge over traditional methods such as oral and injectable routes of drug delivery. Noninvasive drug delivery systems include drug delivery via topical, transdermal-active (device-aided enhanced penetration), transdermal-passive, transocular membrane, and transmucosal membrane, as well as delivery via alveolar membrane from inhaled medication. Patient compliance is much higher when administrated by noninvasive routes due to the lower pain involved in administration; therefore, these techniques are the preferred mode of drug delivery.

Transmucosal Drug Delivery Systems Market, by Geography, 2023 (%)

Traditional drug delivery techniques such as intramuscular, intravenous, oral, and rectal drug administration are not suitable for children and geriatric population. On the other hand, the noninvasive administration of drugs via transmucosal route results in a low dosing frequency and simplified dosing schedules. Moreover, transmucosal drug delivery systems can significantly decrease the cost of clinical use as patients can self-administer these drugs. With the growing demand of transmucosal drug delivery systems, pharmaceutical companies are involved launching formulations that can be delivered through these systems. For instance, in April 2021,Teva Pharmaceuticals USA, Inc., launched its generic version of Casana 1 (mesalamine) suppository medicine for the treatment of active ulcerative proctitis (ulcerative rectal colitis) in the US. Suppositories are noninvasive formulations used in the treatment of gastrointestinal disorders. Thus, the advantages of noninvasive drug delivery fuel the demand for transmucosal drug delivery systems.

The intake of drugs through mucous membranes may cause irritation, inflammation, or allergic reactions at the site of administration. Additionally, all drugs are not suitable for transmucosal delivery, which can be correlated with their physicochemical properties such as molecular size or requirements for systemic distribution. Thus, the pool of drug molecules that can be effectively delivered through mucosal routes is limited. Therefore, the biocompatibility concerns, hampering the suitability of drugs for transmucosal delivery methods, impede the transmucosal drug delivery systems market growth.

Transmucosal Drug Delivery Systems Market Trends:

Integration of nanotechnology into transmucosal drug delivery systems enables the design of nanoscale drug carriers that can enhance the physicochemical properties of the drug and target delivery to the mucosal tissues. Several strategies have been suggested for loading drug-containing nanoparticles (NPs) onto the buccal mucosa for local and systemic applications. There has been significant interest in developing mucoadhesive buccal formulations, particularly hydrogel composites that incorporate mucoadhesive films containing NPs. For instance, a review article published by the Multidisciplinary Digital Publishing Institute (MDPI) in August 2020 discussed various applications of silica NPs in transmucosal drug delivery. The article concluded that silica nanoparticles have shown promise as effective drug nanocarriers for transmucosal drug delivery. This is because they can be easily prepared using simple methods and offer control over particle size and shape, high drug loading capacity, and controlled drug delivery. By synthesizing different types of silica NPs with various functional groups, it is possible to achieve even greater drug delivery efficacy.

Therefore, such technological advancements in the drug delivery systems are expected to bring new market trends in the coming years.

Transmucosal Drug Delivery Systems Market Analysis: Segmental Evaluation

By systems, the market is segmented into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held the largest transmucosal drug delivery systems market share in 2023 and is anticipated to register the highest CAGR from 2023 to 2031. The buccal route of drug administration is a noninvasive, topical method in which drugs are held or applied in the buccal cavity, i.e., the space between the cheek and gums. After their absorption through the oral mucosa, drugs enter the systemic circulation through the jugular vein, bypassing the intestines. This drug administration has many advantages, such as rapid onset of action and a higher bioavailability than the oral route. This method also evades first-pass metabolism, which protects it from degradation in the gastrointestinal (GI) tract.

In terms of end user, the transmucosal drug delivery systems market is segmented into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held the largest transmucosal drug delivery systems market share in 2023 and is anticipated to register the highest CAGR from 2023 to 2031.

Apart from highlighting factors impacting the market, the transmucosal drug delivery systems market report depicts the developments of prominent players. Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc are among the top players operating in the market. The companies have been implementing various strategies that contribute to their growth. These include organic strategies (such as product launches, expansions, and product approvals) and inorganic strategies (such as collaborations and partnerships) that are adopted to stay competitive in the market. 

As per company press releases, a few initiatives taken by key players operating in the global transmucosal drug delivery systems market are listed below:

• In November 2023, Hovione announced the expansion of its nasal drug delivery capabilities through a partnership with Industrial Design Consultancy (IDC). The collaboration has resulted in the development of a family of innovative nasal powder delivery devices. This new technology would help Hovione enhance its nasal drug delivery capabilities.
• In January 2023, Aptar Pharma launched a new product called APF Futurity. It is a metal-free, recyclable, multidose nasal spray pump that is specially designed to deliver nasal saline and other similar over-the-counter (OTC) formulations.

The scope of the transmucosal drug delivery systems market report focuses on North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). In terms of revenue, North America dominated the transmucosal drug delivery systems market share. Furthermore, Asia Pacific is anticipated to record the highest CAGR during 2023–2030. China, India, and Japan are the major contributors to the market growth in this region, which is attributed to the increasing awareness about chronic disorders and the growing number of pharmaceutical and biotechnology companies focusing on this region for their geographic expansion. Additionally, a rising number of research centers and government funding also favor the market growth.  

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com